- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02910206
Etomidate to Improve Outcome in Elderly Patients (EPIC)
December 9, 2020 updated by: Zhihong LU
Comparative Effect of Etomidate and Propofol on Major Complications After Abdominal Surgery in Elderly Patients
Elderly patients have high mortality and postoperative complications rate after surgery, especially postoperative cardiac complications.
A meta-analysis revealed haemodynamic intraoperative events significantly increased the risk of postoperative cardiac complications.To limit the risk, optimize the intraoperative management of circulation is essential.
Anesthetic drug may effect on the haemodynamic intraoperative, reduction of postoperative complications should aimed at choosing the optimal anesthetic drug with minimal effect on haemodynamic.So this study is to explore the comparative efficacy and safety of anesthetic drug (etomidate or propofol) in elderly patients
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1917
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710032
- Xijing hospital, Fourth military medical university
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years to 80 years (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged between 65 and 80 years old.
- Patients scheduled for elective gastrointestinal surgery under general anesthesia.
Exclusion Criteria:
- Expected duration of surgery < 1 or >4 hours
- American Society of Anesthesiologists status >III
- Body Mass Index < 18 kg/m2 or> 25 kg/m2
- Cerebrovascular accident occurred within the previous 3 months,such as stroke or transient ischemic attack
- Unstable angina and myocardial infarction occurred within the previous 3 months
- Patients with serious hepatic dysfunction ( the serum level of alanine transaminase, conjugated bilirubin, aspartate transaminase, alkaline phosphatase or total bilirubin is 2 folds more than upper normal limit) or renal dysfunction(creatinine clearance rate less than 30 milliliter per minute).
- Diabetic patients with complication (diabetic ketoacidosis, hyperosmotic coma,all kinds of infection, macroangiopathy, diabetic nephropathy, retinopathy, diabetic cardiomyopathy, diabetic neuropathy, diabetic foot).
- Preoperative blood pressure more than or equal to 180/110 mmHg
- Confirmed or suspected of narcotic analgesics abusing or long term using
- Taking corticosteroids or immunosuppressive agents for more than 10 days with the previous 6 months or had history of adrenal suppression or immune system disease.
- Patients with thyroid hypofunction.
- Patients with history of asthma.
- Patients with history of surgery within previous 3 months.
- Patients allergic or contraindicated to propofol or etomidate
- Patients participated in other study within the last 30 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: etomidate
etomidate is given for maintenance of general anesthesia,combined with sufentanil and cisatracurium
|
etomidate is given intravenously
sufentanil is given intravenously
Cisatracurium is given intravenously
|
|
Experimental: propofol
propofol is given for maintenance of general anesthesia,combined with sufentanil and cisatracurium
|
sufentanil is given intravenously
Cisatracurium is given intravenously
propofol is given intravenously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants with complications defined by ICD (International codes of diseases)-9
Time Frame: From the moment of giving sufentanil to the moment of discharge from hospital,up to 7 days
|
From the moment of giving sufentanil to the moment of discharge from hospital,up to 7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the time to awake from anesthesia
Time Frame: From stopping etomidate or propofol infusion to awake, approximately 30 minutes
|
From stopping etomidate or propofol infusion to awake, approximately 30 minutes
|
|
|
the time to withdraw tracheal tube from anesthesia
Time Frame: From end of etomidate or propofol infusion to recovery of spontaneous breathing and withdrawal of tracheal tube,approximately 30 minutes
|
From end of etomidate or propofol infusion to recovery of spontaneous breathing and withdrawal of tracheal tube,approximately 30 minutes
|
|
|
the time to discharge from post-anesthesia care unit
Time Frame: From admit into post-anesthesia care unit to discharge from post-anesthesia care unit,on an average of 30 minutes
|
From admit into post-anesthesia care unit to discharge from post-anesthesia care unit,on an average of 30 minutes
|
|
|
the time to discharge from hospital
Time Frame: From end of surgery to discharge from hospital,on an average of 7 days
|
From end of surgery to discharge from hospital,on an average of 7 days
|
|
|
Post Operative Nausea And vomiting score
Time Frame: 6 hours, 24 hours, 48 hours and 72 hours after end of surgery,approximately 6 hours, 24 hours, 48 hours and 72 hours respectively
|
score:0,no nausea and vomiting; 1,nausea without vomiting; 2,vomiting
|
6 hours, 24 hours, 48 hours and 72 hours after end of surgery,approximately 6 hours, 24 hours, 48 hours and 72 hours respectively
|
|
pain on visual analogue scale
Time Frame: 6 hours after end of surgery,approximately 6 hours
|
6 hours after end of surgery,approximately 6 hours
|
|
|
satisfaction on visual analogue scale by the patients
Time Frame: 24 hours after end of surgery
|
patients will be asked to score their satisfaction on anesthesia on a visual analogue, 0 is for extremely unsatisfied, 10 is for totally satisfied
|
24 hours after end of surgery
|
|
comfort on visual analogue scale by the patients
Time Frame: 24 hours after end of surgery
|
patients will be asked to score their comfort during and after anesthesia on a visual analogue, 0 is for extremely unsatisfied, 10 is for totally satisfied
|
24 hours after end of surgery
|
|
incidence of hypotension during anesthesia
Time Frame: from start of surgery to end of surgery, on an average of 2.5 hours
|
hypotension is defined as decrease of systemic blood pressure more than 20% of baseline
|
from start of surgery to end of surgery, on an average of 2.5 hours
|
|
incidence of hypertension during anesthesia
Time Frame: from start of surgery to end of surgery, on an average of 2.5 hours
|
hypotension is defined as increase of systemic blood pressure more than 20% of baseline
|
from start of surgery to end of surgery, on an average of 2.5 hours
|
|
percentage of patients needed vasoactive agents during anesthesia
Time Frame: from start of surgery to end of surgery, on an average of 2.5 hours
|
from start of surgery to end of surgery, on an average of 2.5 hours
|
|
|
concentration of serum Cortisol by radioimmunoassay
Time Frame: 24hours,48hours and 72hours after extubation,approximately 24 hour, 48 hour and 72 hour respectively
|
24hours,48hours and 72hours after extubation,approximately 24 hour, 48 hour and 72 hour respectively
|
|
|
concentration of serum aldosterone by radioimmunoassay
Time Frame: 24hours,48hours and 72hours after extubation,approximately 24 hour, 48 hour and 72 hour respectively
|
24hours,48hours and 72hours after extubation,approximately 24 hour, 48 hour and 72 hour respectively
|
|
|
concentration of serum Adrenocorticotropichormone(ACTH) by radioimmunoassay
Time Frame: 24hours,48hours and 72hours after extubation,approximately 24 hour, 48 hour and 72 hour respectively
|
24hours,48hours and 72hours after extubation,approximately 24 hour, 48 hour and 72 hour respectively
|
|
|
death by 6 months after surgery
Time Frame: from end of surgery to 6 months after surgery
|
from end of surgery to 6 months after surgery
|
|
|
death by 12 months after surgery
Time Frame: from end of surgery to 12 months after surgery
|
from end of surgery to 12 months after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Lize Xiong, PhD, Xijing Hosptial
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Du Y, Chen YJ, He B, Wang YW. The Effects of Single-Dose Etomidate Versus Propofol on Cortisol Levels in Pediatric Patients Undergoing Urologic Surgery: A Randomized Controlled Trial. Anesth Analg. 2015 Dec;121(6):1580-5. doi: 10.1213/ANE.0000000000000981.
- Aghdaii N, Ziyaeifard M, Faritus SZ, Azarfarin R. Hemodynamic Responses to Two Different Anesthesia Regimens in Compromised Left Ventricular Function Patients Undergoing Coronary Artery Bypass Graft Surgery: Etomidate-Midazolam Versus Propofol-Ketamine. Anesth Pain Med. 2015 Jun 22;5(3):e27966. doi: 10.5812/aapm.27966v2. eCollection 2015 Jun.
- Song JC, Lu ZJ, Jiao YF, Yang B, Gao H, Zhang J, Yu WF. Etomidate Anesthesia during ERCP Caused More Stable Haemodynamic Responses Compared with Propofol: A Randomized Clinical Trial. Int J Med Sci. 2015 Jul 3;12(7):559-65. doi: 10.7150/ijms.11521. eCollection 2015.
- Kaushal RP, Vatal A, Pathak R. Effect of etomidate and propofol induction on hemodynamic and endocrine response in patients undergoing coronary artery bypass grafting/mitral valve and aortic valve replacement surgery on cardiopulmonary bypass. Ann Card Anaesth. 2015 Apr-Jun;18(2):172-8. doi: 10.4103/0971-9784.154470.
- Lu Z, Zheng H, Chen Z, Xu S, Chen S, Mi W, Wang T, Chai X, Guo Q, Zhou H, Yu Y, Zheng X, Zhang J, Ai Y, Yu B, Bao H, Zheng H, Huang W, Wu A, Deng X, Ma H, Ma W, Tao L, Yang X, Zhang J, Liu T, Ma HP, Liang W, Wang X, Zhang Y, Du W, Ma T, Xie Y, Xie Y, Li N, Yang Y, Zheng T, Zhang C, Zhao Y, Dong R, Zhang C, Zhang G, Liu K, Wu Y, Fan X, Tan W, Li N, Dong H, Xiong L. Effect of Etomidate vs Propofol for Total Intravenous Anesthesia on Major Postoperative Complications in Older Patients: A Randomized Clinical Trial. JAMA Surg. 2022 Oct 1;157(10):888-895. doi: 10.1001/jamasurg.2022.3338.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 15, 2017
Primary Completion (Actual)
November 20, 2019
Study Completion (Actual)
November 20, 2020
Study Registration Dates
First Submitted
June 30, 2016
First Submitted That Met QC Criteria
September 20, 2016
First Posted (Estimate)
September 21, 2016
Study Record Updates
Last Update Posted (Actual)
December 10, 2020
Last Update Submitted That Met QC Criteria
December 9, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Neuromuscular Agents
- Neuromuscular Blocking Agents
- Propofol
- Sufentanil
- Etomidate
- Cisatracurium
Other Study ID Numbers
- XJH-A-2015-12-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.